Monthly Archives: September 2011

Prix Galien: Pharma R&D and Payers Need to Talk, Yesterday

R&D departments and payers need to communicate early in the drug development process: If pharma is a day late, then payers are likely to be a dollar short, according to panelists at the Galien Forum on Tuesday.
Posted in FDA, leadership, Market Access, pricing, R&D, Strategy | Tagged , , , , | Leave a comment

Bringing Genetic Data into the Clinic

While Big Pharma frets over the costs and risks associated with exploratory endpoints in the clinic and the vagaries of companion diagnostic reimbursement, non-profit organizations like the Multiple Myeloma Research Foundation (MMRF) are stepping in to provide pharmacogenomic research for the next generation of cancer drugs.
Posted in Gene therapy, leadership, R&D, Regulatory, Strategy, Technology | Tagged , , | Leave a comment

Value Isn't Just Dollars and Cents, says Pfizer Exec

Now that 90% of the top 43 countries for drug sales have instituted “significant” cost containment measures, it’s more important than ever to give payers the rest of the story, according to a Pfizer executive.
Posted in Europe, Global, healthcare, Market Access, Marketing, Patient Communication, pricing, Strategy | Tagged | Leave a comment

Deals Don't Need Science To Be A Success

Deals don’t need science to be a success By Brian McGilligan, Partner, Pharmaceutical Practice, PIPC Ex Pfizer R&D boss, John L. LaMattina recently proclaimed that Big Pharma mergers are crippling science. Whether or not you agree, mergers are a core part of business and the chances of safe-guarding future R&D investment in merged companies will […]
Posted in Global, Guest Blog, Strategy | Tagged , , , , | 2 Comments

Obama Deficit Plan Sides With PBMs Over Big Pharma

Amid the flurry of cost-cutting proposals aimed at guiding the Joint Select Committee on Deficit Reduction’s (Super Committee) budgetary blade, the Obama Administration has now weighed in with a proposal to cut $248 billion from Medicare spending over ten years, and $73 billion in Medicaid and other health-related spending. The Obama plan, which would increase […]
Posted in healthcare, leadership, Regulatory, Strategy | Tagged , , , , , | Leave a comment
  • Categories

  • Meta